Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

BACKGROUND: Rash is one of the most common severe adverse events associated with use of vemurafenib for the treatment of melanoma, either as monotherapy or in combination with cobimetinib. The study aimed to identify pre-treatment patient characteristics predictive of developing severe rash with vem...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Hopkins, Ashley M., Rathod, Akash D., Rowland, Andrew, Kichenadasse, Ganessan, Sorich, Michael J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7045585/
https://ncbi.nlm.nih.gov/pubmed/32103736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6659-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller